Together, these stocks offer you a balanced mix of growth and safety. These companies span a number of industries, and many ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...

Dec 12 (Reuters) - The European Medicines ‌Agency's ​committee on Friday ‌recommended extending the use of Eli Lilly's ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Eli Lilly is putting the "obesity field on notice again," an analyst said Thursday after its next-gen delivered 28.7% weight ...

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection ...